Which demographic factors can influence the choice of INH therapy?

The choice of INH (Isoniazid) therapy is significantly influenced by various demographic factors, especially age, liver function, and co-morbidities.

Age is important because younger patients may tolerate INH differently compared to older adults, who might have a higher risk of adverse effects or require adjustments in medication due to slower metabolism. Liver function plays a crucial role since INH is metabolized in the liver; hence, any impairment could lead to drug accumulation and increase the risk of toxicity. Co-morbidities, such as liver diseases (e.g., hepatitis or cirrhosis), can also dictate whether INH is a safe and effective option for a patient, as they may have altered drug handling or additional complications that need to be managed.

Considering these factors ensures that the therapy is tailored to the individual’s health profile, maximizing efficacy while minimizing risk.